Anti-IgE therapy

Jaine Brownell; Thomas B Casale

doi:10.1016/j.iac.2004.06.002

Anti-IgE therapy

Immunol Allergy Clin North Am. 2004 Nov;24(4):551-68, v. doi: 10.1016/j.iac.2004.06.002.

Authors

Jaine Brownell¹, Thomas B Casale

Affiliation

¹ Division of Allergy and Immunology, Department of Medicine, Creighton University School of Medicine, 601 North 30th Street Suite 5850 Omaha, NE 68131, USA.

PMID: 15474858
DOI: 10.1016/j.iac.2004.06.002

Abstract

IgE has a central role in the initiation of allergic hypersensitivity reactions. Pioneered by the development of humanized monoclonal antibodies directed against IgE, anti-IgE therapy represents an original approach to the treatment of allergic disease and has demonstrated promise in preventing the symptoms of asthma, allergic rhinitis, and food allergy. The primary mechanism of action of anti-IgE therapy is the reduction in serum levels of IgE and FcepsilonRI expression on mast cells and basophils.

Publication types

Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Antibodies, Anti-Idiotypic / therapeutic use*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Asthma / drug therapy
Clinical Trials, Phase III as Topic
Food Hypersensitivity / drug therapy
Humans
Immunoglobulin E / biosynthesis
Omalizumab
Receptors, IgE / analysis
Rhinitis, Allergic, Seasonal / drug therapy

Substances

Antibodies, Anti-Idiotypic
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Receptors, IgE
anti-IgE antibodies
Omalizumab
Immunoglobulin E